25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Rafarma Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Rafarma together

I guess you are interested in Rafarma Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Rafarma Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Rafarma Pharmaceuticals Inc

I send you an email if I find something interesting about Rafarma Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Rafarma (30 sec.)










1.2. What can you expect buying and holding a share of Rafarma? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.6%

What is your share worth?

Current worth
$0.12
Expected worth in 1 year
$-0.37
How sure are you?
27.8%

+ What do you gain per year?

Total Gains per Share
$-0.49
Return On Investment
-505.4%

For what price can you sell your share?

Current Price per Share
$0.10
Expected price per share
$0.05 - $0.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Rafarma (5 min.)




Live pricePrice per Share (EOD)
$0.10
Intrinsic Value Per Share
$11.63 - $14.07
Total Value Per Share
$11.75 - $14.19

2.2. Growth of Rafarma (5 min.)




Is Rafarma growing?

Current yearPrevious yearGrowGrow %
How rich?$10.8m$75m-$45.8m-156.6%

How much money is Rafarma making?

Current yearPrevious yearGrowGrow %
Making money-$325.4k$794k-$1.1m-344.0%
Net Profit Margin3.3%7.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Rafarma (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Rafarma?

Welcome investor! Rafarma's management wants to use your money to grow the business. In return you get a share of Rafarma.

First you should know what it really means to hold a share of Rafarma. And how you can make/lose money.

Speculation

The Price per Share of Rafarma is $0.0973. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rafarma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rafarma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.12. Based on the TTM, the Book Value Change Per Share is $-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rafarma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.2%0.00-3.8%0.019.3%0.0113.4%0.0111.9%
Usd Book Value Change Per Share0.004.1%-0.12-126.4%-0.10-103.0%-0.32-328.7%-0.28-292.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.002.5%0.002.2%
Usd Total Gains Per Share0.004.1%-0.12-126.4%-0.10-103.0%-0.32-326.2%-0.28-289.9%
Usd Price Per Share0.04-0.16-0.42-0.63-0.56-
Price to Earnings Ratio45.17-48.42-64.75-97.93-78.25-
Price-to-Total Gains Ratio8.78-1.85--3.91--0.39--15.37-
Price to Book Ratio0.28-0.73-0.48-0.97-0.87-
Price-to-Total Gains Ratio8.78-1.85--3.91--0.39--15.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0973
Number of shares10277
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.12-0.32
Usd Total Gains Per Share-0.12-0.32
Gains per Quarter (10277 shares)-1,263.45-3,262.25
Gains per Year (10277 shares)-5,053.78-13,049.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-5054-5064100-13149-13059
20-10108-10118200-26298-26108
30-15161-15172300-39447-39157
40-20215-20226400-52597-52206
50-25269-25280501-65746-65255
60-30323-30334601-78895-78304
70-35376-35388701-92044-91353
80-40430-40442801-105193-104402
90-45484-45496901-118342-117451
100-50538-505501001-131491-130500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.02.00.060.0%11.03.00.078.6%13.03.00.081.3%13.05.00.072.2%13.07.00.065.0%
Book Value Change Per Share1.02.02.020.0%3.08.03.021.4%4.09.03.025.0%5.010.03.027.8%6.010.04.030.0%
Dividend per Share0.00.05.00.0%1.00.013.07.1%1.00.015.06.3%1.00.017.05.6%1.00.019.05.0%
Total Gains per Share1.02.02.020.0%3.08.03.021.4%4.09.03.025.0%5.010.03.027.8%6.010.04.030.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Rafarma Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.004-0.123+3183%-0.100+2614%-0.320+8121%-0.284+7229%
Book Value Per Share--0.1240.333-63%0.855-86%0.680-82%1.187-90%
Current Ratio--1.1361.823-38%3.321-66%2.775-59%2.467-54%
Debt To Asset Ratio--0.3330.203+64%0.187+78%0.201+66%0.178+87%
Debt To Equity Ratio--0.5000.267+87%0.231+117%0.255+96%0.227+121%
Dividend Per Share----0%-0%0.002-100%0.002-100%
Eps--0.000-0.004+2014%0.009-98%0.013-99%0.012-98%
Free Cash Flow Per Share---0.010-0.040+307%-0.027+175%-0.023+131%-0.023+131%
Free Cash Flow To Equity Per Share---0.010-0.039+297%-0.025+156%-0.026+161%-0.026+161%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--14.068--------
Intrinsic Value_10Y_min--11.626--------
Intrinsic Value_1Y_max--0.090--------
Intrinsic Value_1Y_min--0.088--------
Intrinsic Value_3Y_max--1.276--------
Intrinsic Value_3Y_min--1.198--------
Intrinsic Value_5Y_max--3.675--------
Intrinsic Value_5Y_min--3.324--------
Market Cap8539729.100+64%3071845.00014183147.200-78%36511072.000-92%55704122.555-94%49641062.566-94%
Net Profit Margin--0.1570.033+377%0.075+109%0.076+107%0.068+133%
Operating Margin----0.0380%0.035-100%-0.0010%-0.0010%
Operating Ratio--0.7500.937-20%0.876-14%0.887-15%0.789-5%
Pb Ratio0.786+64%0.2830.734-61%0.480-41%0.974-71%0.866-67%
Pe Ratio125.584+64%45.17448.417-7%64.749-30%97.934-54%78.251-42%
Price Per Share0.097+64%0.0350.162-78%0.416-92%0.630-94%0.562-94%
Price To Free Cash Flow Ratio-2.482-178%-0.8937.464-112%-2.139+139%0.843-206%0.749-219%
Price To Total Gains Ratio24.399+64%8.7771.853+374%-3.915+145%-0.391+104%-15.369+275%
Quick Ratio--0.8911.349-34%2.050-57%1.764-49%1.568-43%
Return On Assets--0.001-0.003+428%0.010-90%0.013-92%0.011-91%
Return On Equity--0.002-0.004+380%0.012-87%0.016-90%0.014-89%
Total Gains Per Share--0.004-0.123+3183%-0.100+2614%-0.317+8060%-0.282+7174%
Usd Book Value--10859000.00029259400.000-63%75070000.000-86%59966499.938-82%104419372.111-90%
Usd Book Value Change Per Share--0.004-0.123+3183%-0.100+2614%-0.320+8121%-0.284+7229%
Usd Book Value Per Share--0.1240.333-63%0.855-86%0.680-82%1.187-90%
Usd Dividend Per Share----0%-0%0.002-100%0.002-100%
Usd Eps--0.000-0.004+2014%0.009-98%0.013-99%0.012-98%
Usd Free Cash Flow---860000.000-3500800.000+307%-2363000.000+175%-1975687.500+130%-1756166.667+104%
Usd Free Cash Flow Per Share---0.010-0.040+307%-0.027+175%-0.023+131%-0.023+131%
Usd Free Cash Flow To Equity Per Share---0.010-0.039+297%-0.025+156%-0.026+161%-0.026+161%
Usd Market Cap8539729.100+64%3071845.00014183147.200-78%36511072.000-92%55704122.555-94%49641062.566-94%
Usd Price Per Share0.097+64%0.0350.162-78%0.416-92%0.630-94%0.562-94%
Usd Profit--17000.000-325400.000+2014%794000.000-98%1155125.000-99%1026378.611-98%
Usd Revenue--108000.0002381200.000-95%10007000.000-99%11592375.000-99%10304333.333-99%
Usd Total Gains Per Share--0.004-0.123+3183%-0.100+2614%-0.317+8060%-0.282+7174%
 EOD+5 -3MRQTTM+21 -11YOY+15 -185Y+16 -1810Y+16 -18

3.3 Fundamental Score

Let's check the fundamental score of Rafarma Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15125.584
Price to Book Ratio (EOD)Between0-10.786
Net Profit Margin (MRQ)Greater than00.157
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.891
Current Ratio (MRQ)Greater than11.136
Debt to Asset Ratio (MRQ)Less than10.333
Debt to Equity Ratio (MRQ)Less than10.500
Return on Equity (MRQ)Greater than0.150.002
Return on Assets (MRQ)Greater than0.050.001
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Rafarma Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.790
Ma 20Greater thanMa 500.104
Ma 50Greater thanMa 1000.069
Ma 100Greater thanMa 2000.063
OpenGreater thanClose0.097
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Rafarma Pharmaceuticals Inc

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Fundamental data was last updated by Penke on 2024-11-03 23:36:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Rafarma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 15.7% means that $0.16 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 15.7%. The company is making a huge profit. +2
  • The TTM is 3.3%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ15.7%TTM3.3%+12.4%
TTM3.3%YOY7.5%-4.2%
TTM3.3%5Y7.6%-4.3%
5Y7.6%10Y6.8%+0.8%
4.3.1.2. Return on Assets

Shows how efficient Rafarma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.1% Return on Assets means that Rafarma generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.1%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.1%TTM-0.3%+0.4%
TTM-0.3%YOY1.0%-1.3%
TTM-0.3%5Y1.3%-1.6%
5Y1.3%10Y1.1%+0.1%
4.3.1.3. Return on Equity

Shows how efficient Rafarma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.2% Return on Equity means Rafarma generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -0.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.2%TTM-0.4%+0.6%
TTM-0.4%YOY1.2%-1.7%
TTM-0.4%5Y1.6%-2.0%
5Y1.6%10Y1.4%+0.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Rafarma Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Rafarma is operating .

  • Measures how much profit Rafarma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3.8%+3.8%
TTM-3.8%YOY3.5%-7.3%
TTM-3.8%5Y-0.1%-3.7%
5Y-0.1%10Y-0.1%0.0%
4.3.2.2. Operating Ratio

Measures how efficient Rafarma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.75 means that the operating costs are $0.75 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.750. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.937. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.750TTM0.937-0.187
TTM0.937YOY0.876+0.061
TTM0.9375Y0.887+0.050
5Y0.88710Y0.789+0.099
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Rafarma Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Rafarma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.14 means the company has $1.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 1.136. The company is just able to pay all its short-term debts.
  • The TTM is 1.823. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.136TTM1.823-0.688
TTM1.823YOY3.321-1.498
TTM1.8235Y2.775-0.952
5Y2.77510Y2.467+0.308
4.4.3.2. Quick Ratio

Measures if Rafarma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.89 means the company can pay off $0.89 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.891. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.349. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ0.891TTM1.349-0.458
TTM1.349YOY2.050-0.701
TTM1.3495Y1.764-0.415
5Y1.76410Y1.568+0.196
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Rafarma Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Rafarma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rafarma to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.33 means that Rafarma assets are financed with 33.3% credit (debt) and the remaining percentage (100% - 33.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.333. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.203. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.333TTM0.203+0.130
TTM0.203YOY0.187+0.016
TTM0.2035Y0.201+0.003
5Y0.20110Y0.178+0.022
4.5.4.2. Debt to Equity Ratio

Measures if Rafarma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 50.0% means that company has $0.50 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rafarma Pharmaceuticals Inc:

  • The MRQ is 0.500. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.267. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.500TTM0.267+0.233
TTM0.267YOY0.231+0.036
TTM0.2675Y0.255+0.012
5Y0.25510Y0.227+0.028
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rafarma generates.

  • Above 15 is considered overpriced but always compare Rafarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 45.17 means the investor is paying $45.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rafarma Pharmaceuticals Inc:

  • The EOD is 125.584. Based on the earnings, the company is expensive. -2
  • The MRQ is 45.174. Based on the earnings, the company is overpriced. -1
  • The TTM is 48.417. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD125.584MRQ45.174+80.410
MRQ45.174TTM48.417-3.243
TTM48.417YOY64.749-16.332
TTM48.4175Y97.934-49.517
5Y97.93410Y78.251+19.683
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rafarma Pharmaceuticals Inc:

  • The EOD is -2.482. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.893. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 7.464. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-2.482MRQ-0.893-1.590
MRQ-0.893TTM7.464-8.357
TTM7.464YOY-2.139+9.602
TTM7.4645Y0.843+6.621
5Y0.84310Y0.749+0.094
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Rafarma is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Rafarma Pharmaceuticals Inc:

  • The EOD is 0.786. Based on the equity, the company is cheap. +2
  • The MRQ is 0.283. Based on the equity, the company is cheap. +2
  • The TTM is 0.734. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.786MRQ0.283+0.504
MRQ0.283TTM0.734-0.451
TTM0.734YOY0.480+0.254
TTM0.7345Y0.974-0.240
5Y0.97410Y0.866+0.108
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-08-312023-09-302024-02-292024-03-312024-06-30
Other Current Liabilities  4080408-32286086-88-2



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets16,290
Total Liabilities5,431
Total Stockholder Equity10,859
 As reported
Total Liabilities 5,431
Total Stockholder Equity+ 10,859
Total Assets = 16,290

Assets

Total Assets16,290
Total Current Assets6,167
Long-term Assets10,123
Total Current Assets
Cash And Cash Equivalents 73
Net Receivables 4,766
Inventory 1,328
Total Current Assets  (as reported)6,167
Total Current Assets  (calculated)6,167
+/-0
Long-term Assets
Property Plant Equipment 113
Long-term Assets Other 10,010
Long-term Assets  (as reported)10,123
Long-term Assets  (calculated)10,123
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,431
Long-term Liabilities0
Total Stockholder Equity10,859
Total Current Liabilities
Accounts payable 5,433
Other Current Liabilities -2
Total Current Liabilities  (as reported)5,431
Total Current Liabilities  (calculated)5,431
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock87
Retained Earnings 758
Accumulated Other Comprehensive Income 10,002
Total Stockholder Equity (as reported)10,859
Total Stockholder Equity (calculated)10,847
+/- 12
Other
Cash and Short Term Investments 73
Common Stock Shares Outstanding 87,767
Liabilities and Stockholders Equity 16,290
Net Debt -73
Net Working Capital 736



6.3. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302024-03-312024-02-292023-09-302023-08-312023-06-302023-05-312023-03-312023-02-282022-12-312022-11-302022-09-302022-08-312022-06-302022-05-312022-03-312022-02-282021-12-312021-11-302021-09-302021-08-312021-06-302021-05-312021-03-312021-02-282015-05-312015-02-282014-05-312014-02-28
> Total Assets 
461,762
461,762
460,332
460,332
75,630
75,630
85,139
85,139
88,167
88,167
89,344
89,344
81,601
81,601
132,313
132,313
116,460
116,460
98,321
98,321
87,315
87,315
79,670
79,670
72,057
72,057
12,163
12,163
16,290
16,29012,16312,16372,05772,05779,67079,67087,31587,31598,32198,321116,460116,460132,313132,31381,60181,60189,34489,34488,16788,16785,13985,13975,63075,630460,332460,332461,762461,762
   > Total Current Assets 
1,430
1,430
0
0
46,945
46,945
51,606
51,606
53,930
53,930
55,243
55,243
46,771
46,771
74,277
74,277
62,238
62,238
53,970
53,970
46,195
46,195
40,635
40,635
35,652
35,652
2,039
2,039
6,167
6,1672,0392,03935,65235,65240,63540,63546,19546,19553,97053,97062,23862,23874,27774,27746,77146,77155,24355,24353,93053,93051,60651,60646,94546,945001,4301,430
       Cash And Cash Equivalents 
0
0
0
0
2,933
2,933
11,275
11,275
15,715
15,715
13,596
13,596
9,957
9,957
17,118
17,118
16,433
16,433
18,048
18,048
15,159
15,159
13,978
13,978
8,275
8,275
66
66
73
7366668,2758,27513,97813,97815,15915,15918,04818,04816,43316,43317,11817,1189,9579,95713,59613,59615,71515,71511,27511,2752,9332,9330000
       Short-term Investments 
0
0
0
0
2,115
2,115
93
93
23
23
27
27
142
142
83
83
51
51
781
781
25
25
23
23
27
27
0
0
0
000272723232525781781515183831421422727232393932,1152,1150000
       Net Receivables 
1,430
1,430
0
0
22,454
22,454
19,481
19,481
17,990
17,990
20,318
20,318
17,879
17,879
23,154
23,154
17,394
17,394
15,453
15,453
13,481
13,481
12,064
12,064
14,291
14,291
1,880
1,880
4,766
4,7661,8801,88014,29114,29112,06412,06413,48113,48115,45315,45317,39417,39423,15423,15417,87917,87920,31820,31817,99017,99019,48119,48122,45422,454001,4301,430
       Other Current Assets 
0
0
0
0
0
0
0
0
-1
-1
0
0
0
0
0
0
-1
-1
-1
-1
1
1
0
0
-1
-1
0
0
0
000-1-10011-1-1-1-1000000-1-100000000
   > Long-term Assets 
0
0
0
0
28,685
28,685
33,533
33,533
34,237
34,237
34,101
34,101
34,830
34,830
58,036
58,036
54,222
54,222
44,351
44,351
41,120
41,120
39,035
39,035
36,405
36,405
10,124
10,124
10,123
10,12310,12410,12436,40536,40539,03539,03541,12041,12044,35144,35154,22254,22258,03658,03634,83034,83034,10134,10134,23734,23733,53333,53328,68528,6850000
       Property Plant Equipment 
0
0
0
0
23,296
23,296
27,702
27,702
28,524
28,524
28,468
28,468
29,683
29,683
49,931
49,931
46,953
46,953
40,216
40,216
37,328
37,328
36,088
36,088
33,755
33,755
115
115
113
11311511533,75533,75536,08836,08837,32837,32840,21640,21646,95346,95349,93149,93129,68329,68328,46828,46828,52428,52427,70227,70223,29623,2960000
       Long Term Investments 
460,332
460,332
460,332
460,332
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000460,332460,332460,332460,332
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000
> Total Liabilities 
1,799
1,799
288
292
14,516
14,516
17,986
17,986
20,870
20,870
19,839
19,839
17,657
17,657
23,509
23,509
19,725
19,725
20,427
20,427
16,212
16,212
14,861
14,861
14,847
14,847
1,654
1,654
5,431
5,4311,6541,65414,84714,84714,86114,86116,21216,21220,42720,42719,72519,72523,50923,50917,65717,65719,83919,83920,87020,87017,98617,98614,51614,5162922881,7991,799
   > Total Current Liabilities 
1,470
1,470
288
292
13,908
13,908
17,300
17,300
19,342
19,342
19,054
19,054
15,704
15,704
20,302
20,302
16,513
16,513
17,785
17,785
13,840
13,840
12,575
12,575
12,931
12,931
1,654
1,654
5,431
5,4311,6541,65412,93112,93112,57512,57513,84013,84017,78517,78516,51316,51320,30220,30215,70415,70419,05419,05419,34219,34217,30017,30013,90813,9082922881,4701,470
       Short-term Debt 
1,430
1,430
178
178
49
49
1,670
1,670
1,914
1,914
1,612
1,612
267
267
1,055
1,055
1,399
1,399
360
360
349
349
1,413
1,413
1,850
1,850
0
0
0
0001,8501,8501,4131,4133493493603601,3991,3991,0551,0552672671,6121,6121,9141,9141,6701,67049491781781,4301,430
       Short Long Term Debt 
1,430
1,430
178
178
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000001781781,4301,430
       Accounts payable 
40
40
110
114
13,619
13,619
15,366
15,366
17,182
17,182
17,224
17,224
15,188
15,188
18,828
18,828
14,801
14,801
17,179
17,179
13,239
13,239
10,944
10,944
10,673
10,673
1,568
1,568
5,433
5,4331,5681,56810,67310,67310,94410,94413,23913,23917,17917,17914,80114,80118,82818,82815,18815,18817,22417,22417,18217,18215,36615,36613,61913,6191141104040
       Other Current Liabilities 
0
0
0
0
240
240
264
264
246
246
218
218
249
249
419
419
313
313
246
246
252
252
218
218
408
408
86
86
-2
-286864084082182182522522462463133134194192492492182182462462642642402400000
   > Long-term Liabilities 
0
0
0
0
608
608
686
686
1,528
1,528
785
785
1,953
1,953
3,207
3,207
3,212
3,212
2,642
2,642
2,372
2,372
2,286
2,286
1,916
1,916
0
0
0
0001,9161,9162,2862,2862,3722,3722,6422,6423,2123,2123,2073,2071,9531,9537857851,5281,5286866866086080000
> Total Stockholder Equity
459,964
359,968
460,044
460,041
61,114
61,114
67,153
67,153
68,028
68,028
69,506
69,506
63,944
63,944
108,804
108,804
96,735
96,735
77,895
77,895
71,103
71,103
64,809
64,809
57,209
57,209
10,509
10,509
10,859
10,85910,50910,50957,20957,20964,80964,80971,10371,10377,89577,89596,73596,735108,804108,80463,94463,94469,50669,50668,02868,02867,15367,15361,11461,114460,041460,044359,968459,964
   Common Stock
78
78
84
84
8,777
8,777
8,777
8,777
8,777
8,777
87
87
87
87
88
88
88
88
87
87
87
87
87
87
87
87
37
37
87
873737878787878787878788888888878787878,7778,7778,7778,7778,7778,77784847878
   Retained Earnings Total Equity00000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
8,777
8,777
8,777
8,777
8,777
8,777
87
87
87
87
31,796
31,796
28,332
28,332
23,122
23,122
21,097
21,097
18,686
18,686
16,692
16,692
10,002
10,002
10,002
10,00210,00210,00216,69216,69218,68618,68621,09721,09723,12223,12228,33228,33231,79631,796878787878,7778,7778,7778,7778,7778,7770000
   Capital Surplus 00000000000000000000000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-8,777
-8,777
-7,644
-7,644
5,452
5,452
9,681
9,681
19,258
19,258
31,708
0
-1
-1
1
1
1
1
18,599
0
1
1
50
50
0
0505011018,5991111-1-1031,70819,25819,2589,6819,6815,4525,452-7,644-7,644-8,777-8,7770000



6.4. Balance Sheets

All numbers in thousands.




6.5. Cash Flows

All numbers in thousands.




6.6. Income Statements

All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue10,135
Cost of Revenue-9,535
Gross Profit600600
 
Operating Income (+$)
Gross Profit600
Operating Expense-287
Operating Income313313
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense2870
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income313
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)360266
EBIT - interestExpense = 145
360
273
Interest Expense0
Earnings Before Interest and Taxes (EBIT)145360
Earnings Before Interest and Taxes (EBITDA)313
 
After tax Income (+$)
Income Before Tax360
Tax Provision-0
Net Income From Continuing Ops0360
Net Income273
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses9,822
Total Other Income/Expenses Net470
 

Technical Analysis of Rafarma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rafarma. The general trend of Rafarma is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rafarma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rafarma Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.12 < 0.12 < 0.12.

The bearish price targets are: 0.077 > 0.075 > 0.05.

Tweet this
Rafarma Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rafarma Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rafarma Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rafarma Pharmaceuticals Inc. The current macd is 0.00997764.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rafarma price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Rafarma. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Rafarma price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Rafarma Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartRafarma Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rafarma Pharmaceuticals Inc. The current adx is 26.96.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Rafarma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Rafarma Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rafarma Pharmaceuticals Inc. The current sar is 0.07818291.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Rafarma Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rafarma Pharmaceuticals Inc. The current rsi is 51.79. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Rafarma Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartRafarma Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rafarma Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rafarma price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Rafarma Pharmaceuticals Inc Daily Stochastic Oscillator ChartRafarma Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rafarma Pharmaceuticals Inc. The current cci is -42.64024666.

Rafarma Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartRafarma Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rafarma Pharmaceuticals Inc. The current cmo is -6.14767491.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Rafarma Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartRafarma Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rafarma Pharmaceuticals Inc. The current willr is -50.44444444.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Rafarma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Rafarma Pharmaceuticals Inc Daily Williams %R ChartRafarma Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rafarma Pharmaceuticals Inc.

Rafarma Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rafarma Pharmaceuticals Inc. The current atr is 0.01300901.

Rafarma Pharmaceuticals Inc Daily Average True Range (ATR) ChartRafarma Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rafarma Pharmaceuticals Inc. The current obv is -86,902.

Rafarma Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartRafarma Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rafarma Pharmaceuticals Inc. The current mfi is 48.91.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Rafarma Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartRafarma Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rafarma Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Rafarma Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rafarma Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.790
Ma 20Greater thanMa 500.104
Ma 50Greater thanMa 1000.069
Ma 100Greater thanMa 2000.063
OpenGreater thanClose0.097
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Rafarma with someone you think should read this too:
  • Are you bullish or bearish on Rafarma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rafarma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rafarma Pharmaceuticals Inc

I send you an email if I find something interesting about Rafarma Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Rafarma Pharmaceuticals Inc.

Receive notifications about Rafarma Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.